Media stories about Intec Pharma (NASDAQ:NTEC) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intec Pharma earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.5956029969651 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several brokerages recently weighed in on NTEC. Zacks Investment Research upgraded shares of Intec Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. CIBC restated an “outperform” rating and issued a $15.00 price target (up previously from $10.00) on shares of Intec Pharma in a research report on Thursday, September 21st. Oppenheimer boosted their price target on shares of Intec Pharma from $10.00 to $15.00 and gave the stock an “outperform” rating in a research report on Thursday, September 21st. Maxim Group set a $8.00 price objective on shares of Intec Pharma and gave the company a “buy” rating in a research report on Friday, November 17th. Finally, ValuEngine cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Intec Pharma has a consensus rating of “Buy” and a consensus price target of $11.00.

Intec Pharma (NASDAQ NTEC) traded up $0.15 during mid-day trading on Thursday, reaching $5.30. 276,200 shares of the company’s stock were exchanged, compared to its average volume of 47,562. Intec Pharma has a fifty-two week low of $4.20 and a fifty-two week high of $9.80.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/12/14/intec-pharma-ntec-receiving-somewhat-positive-news-coverage-report-shows.html.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Insider Buying and Selling by Quarter for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.